St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits?

Almost all of Australia’s economists are predicting the Reserve Bank of Australia (RBA) will raise the official cash rate next year to around 3% from its current level of 2.5%.

But they’re most likely wrong.

Not that that’s something new.

As the saying goes, economists have predicted 8 out of the past 3 recessions.

But the most likely scenario appears to be a further cut to the cash rate. Weakness in the Australian and global economies, coupled with rising unemployment, a massive budget deficit, falling GDP and mining investment steadily declining.

An additional factor appears to be the heat coming out of the property market. When the RBA lowers rates, mortgage rates tend to follow, which can see property prices get out of control, as investors and home buyers take advantage of the cheap debt.

If property prices are cooling, it means the RBA has less to worry about should it feel the need to lower rates to boost other sectors of the economy.

Bond markets are already pricing in an 80% chance of a 25 basis point cut to interest rates in 2015. Economists on the other hand appear to be disregarding the bond market, forecasting interest rates to rise, following in the steps of the US Federal Reserve.
Global Asset manager AllianceBernstein suggested last week that economists were underestimating the impact of crashing commodity prices. Australia’s top three exports last year were iron ore, coal and natural gas. And the top ten includes gold, petroleum and aluminium.

Deutsche Bank economists now also expect the RBA to cut rates by 50 basis points, or half a percent, taking the cash rate to 2%.

Should the RBA cut rates next year, that is likely to see the Australian dollar fall further – as it becomes less attractive for global investors to park their cash in the country. Expectations the US will raise interest rates will compound the effect, further pushing down our dollar.

Not only would the dollar fall, but term deposit rates, which are already barely covering the hidden cost of inflation, would also fall – making dividend paying stocks even more attractive.

Could we see the Australian dollar at 60 US cents in 2015?

It’s a distinct possibility, giving our exporters and companies with large offshore operations a massive leg up. Companies I already own including CSL Limited (ASX: CSL), Cochlear Limited (ASX: COH), Flight Centre Travel Group Ltd (ASX: FLT) and TFS Corporation Limited (ASX: TFC) would be big beneficiaries.

Now might be the time to consider how you could take advantage of the Aussie dollar trading at 85 US cents.

Source: http://www.fool.com.au back

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital more

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month more

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold more

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones more

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more